Alzheimer's disease as neurodegenerative disorder;Choroba Alzheimera jako przykład schorzenia neurodegeneracyjnego

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 60, Issue , 2006, Pages 209-216

  Zabłocka, Agnieszka ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Alzheimer's disease; Immunological system; Neurodegeneration

Indexed keywords

CYTOKINE; FREE RADICAL; NITRIC OXIDE;

ALZHEIMER DISEASE; ANIMAL; BIOSYNTHESIS; BLOOD BRAIN BARRIER; GLIA; HUMAN; IMMUNOLOGY; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; REVIEW;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; CYTOKINES; ENGLISH ABSTRACT; FREE RADICALS; HUMANS; NEUROGLIA; NEURONS; NITRIC OXIDE;

EID: 33846106057     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Aarli J.A.: Role of cytokines in neurological disorders. Curr. Med. Chem., 2003; 10: 1931-1937
2. Akama K.T., Albanese C., Pestell R.G., van Eldik L.J.: Amyloid b-peptide stimulates nitric oxide production in astrocytes through an NFkB-dependent mechanism. Proc. Natl. Acad. Sci USA, 1998; 95: 5795-5800
3. Akama K.T., Van Eldik L.J.: b-amyloid stimulation of inducible nitric-oxide synthase in astrocytes in interleukin 1b and tumor necrosis factor-A (TNF-a)-dependent, and involves a TNF-A-receptor-associated factor and NF-kB-inducing kinase-dependent signaling mechanism. J. Biol. Chem., 2000; 275: 7918-7924
4. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T.: Inflammation and Alzheimer's disease. Neurobiology of Aging, 2000; 21: 383-421
5. Ali C., Nicole O., Docagne F., Lesne S., MacKenzie E.T., Nouvelot A., Buisson A., Vivien D.: Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitotoxicity in the brain. J. Cereb. Blood Flow Metab., 2000; 20: 956-966
6. Allan S.M., Rothwell N.J.: Cytokines and acute neurodegeneration. Nature Rev. Neurosci., 2001; 2: 734-744
7. Arbel M., Yacoby I., Solomon B.: Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. Proc. Natl. Acad. Sci. USA, 2005; 102: 7718-7723
8. Barger S.W., Horster D., Furukawa K., Goodman Y., Krieglstein J., Mattson M.P.: Tumor necrosis factors a and b protect neurons against amyloid b peptide toxicity. Proc. Natl. Acad. Sci. USA, 1995; 92: 9328-9332
9. Bartosz G.: Medycyna pisana na nowo. W: Druga twarz tlenu. Wolne rodniki w przyrodzie. Wyd. PWN 2003: 255-257
10. Behl C.: Alzheimer's disease and oxidative stress. Implications for novel therapeutic approaches. Prog. Neurobiol., 1999; 57: 301-323
11. Beloosesky Y., Salman H., Bergman M., Bessler H., Djaldetti M.: Cytokine levels and phagocytic activity in patients with Alzheimer's disease. Gerontology, 2002; 48: 128-132
12. Bilikiewicz A., Gaus W.: Colostrinin (a naturally occurring, prolinerich polipeptide mixture) in the treatment of Alzheimer's disease. J. Alzheimer's Disease, 2004; 6: 17-26
13. Bouras C., Riederer B.M., Kovari E., Hof P.R., Giannakopoulos P.: Humoral immunity in brain aging and Alzheimer's disease. Brain Res. Brain Res. Rev., 2005; 48: 477-487
14. Braddock M.: Safely slowing down the decline in Alzheimer's disease: gene therapy shows potential. Expert Opin. Investig. Drugs, 2005; 14: 913-915
15. Brera B., Serrano A., de Ceballos M.L.: b-amyloid peptides are cytotoxic to astrocytes in culture: A role for oxidative stress. Neurobiol. Dis., 2000; 7: 395-405
16. Bullock R.: Galantamine: use in Alzheimer's disease and related disorders. Expert Rev. Neurother., 2004; 4: 153-163
17. Buonocore G., Perrone S., Bracci R.: Free radicals and brain damage in the newborn. Biol. Neonate, 2001; 79: 180-186
18. Butterfield D.A., Griffin S., Munch G., Pasinetti G.M.: Amyloid b-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J Alzheimer's Dis., 2002; 4: 193-201
19. Cardoso S.M., Oliveira C.R.: Inhibition of NF-kB renders cells more vulnerable to apoptosis induced by amyloid beta peptides. Free Radic. Res., 2003; 37: 967-973
20. Chauhan N., Wang K.C., Węgiel J., Malik M.N.: Walnut extract inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Curr. Alzheimer Res., 2004; 1: 183-188
21. Checler F., Alves da Costa C., Ayral E., Andrau D., Dumanchin C., Farzan M., Hernandez J.F., Martinez J., Lefranc-Jullien S., Marambaud P., Pasini A., Petit A., Phiel C., Robert P., St George-Hyslop P., Wilk S.: JLK inhibitors: isocoumarin compounds as putative probes to selectively target the gamma-secretase pathway. Curr. Alzheimer Res., 2005; 2: 327-334
22. Cho H.S, Hyman B.T., Greenberg S.M., Rebeck G.W.: Qantitation of apoE domains in Alzheimer disease brain suggest a role of apoE in amyloid beta aggregation. J. Neuropathol. Exp. Neurol., 2001; 60: 342-349
23. Choudhary M.I., Nawaz S.A., Zaheer-ul-Haq, Azim M.K., Ghayur M.N., Lodhi M.A., Jalil S., Khalid A., Ahmed A., Rode B.M., Atta-ur-Rahman, Gilani A.U., Ahmad V.U.: Juliflorine: A potent natural peripheral anionic-site-binding inhibitor of acetylcholinesterase with calciumchannel blocking potential, a leading candidate for Alzheimer's disease therapy. Biochem. Biophys. Res. Commun., 2005; 332: 1171-1177
24. Clancy R.M., Abramson S.B.: Nitric oxide: A novel mediator of inflammation. Proc. Soc. Exp. Biol. Med., 1995; 210: 93-101
25. Clancy R.M., Amin A.R., Abramson S.B.: The role of nitric oxide in inflammation and immunity. Arthritis Rheum., 1998; 41: 1141-1151
26. Combs C.K., Karlo J.K., Kao S.C., Landreth G.E.: b-amyloid stimulation of microglia and monocytes results in TNFa-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci., 2001; 21: 1179-1188
27. Correale J., Villa A.: The neuroprotective role of the inflammation in nervous system injuries. J. Neurol., 2004; 251: 1304-1316
28. De al Monte S.M., Ghanbari H., Averback P., Wands J.R.: AD7c-NTP biomarker for Alzheimer's disease. Alzheimer's Report, 1999; 2: 327-332
29. Del Bo R., Angeretti N., Lucca E., de Simoni M.G., Forloni G.: Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and b-amyloid production in cultures. Neurosci. Lett., 1995; 188: 70-74
30. Della Bianca V., Dusi S., Bianchini E., Dal Pra I., Rossi F.: b amyloid activates the O2-forming NADPH oxidase in microglia, monocytes and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J. Biol. Chem., 1999; 274; 15493-15499
31. Dinh-Xuan A.T., Texereau J.: Measuring exhaled nitric oxide: not only a matter of how-but also why-should we do it? Eur. Respir. J., 1998; 12: 1005-1007
32. Dinsmore J.H.: Treatment of neurodegenerative diseases with neural cell transplantation. Expert Opin. Investig. Drugs, 1998; 7: 527-534
33. Dobryszycka W., Gąsiorowski K., Leszek J.: Metaboliczne podstawy choroby Alzheimera. W: Demencje wieku podeszłego. Patomechanizm i strategie leczenia. Wyd. Continuo, 2004: 9-45
34. Dobryszycka W., Leszek J., Rymaszewska J.: Blaszki starcze. W: Choroba Alzheimera. Patogeneza, diagnostyka, leczenie. Wyd. Continuo, 2002: 13-25
35. Dodel R.C., Hampel H., Du Y.: Immunotherapy for Alzheimer's disease. Lancet Neurol., 2003; 2: 215-220
36. Dong Y., Benveniste E.N.: Immune function of astrocytes. Glia, 2001; 36: 180-190
37. Dumery L., Bourdel F., Soussan Y., Fialkowsky A., Viale S., Nicolas P., Reboud-Ravaux M.: b-amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease. Pathol. Biol. (Paris), 2001; 49: 72-85
38. Ensoli F, Fiorelli V., Muratori D.S., De Cristofaro M., Topino S., Novi A., Luzi G., Sirianni M.C.: Immune-derived cytokines in the nervous system: epigenetic, instructive signals or neuropathogenic mediators?. Crit. Revs Immunol., 1999; 19: 97-116
39. Fang F.C.: Mechanisms of nitric oxide-related antimicrobioidal activity. J. Clin. Invest., 1997; 99: 2818-2825
40. Fraser P.E., Yang D.S., Yu G., Levesque L., Nishimura M., Arawaka S., Serpell L.C., Rogaeva E., St George-Hyslop P.: Presenilin, strukture, function and role in Alzheimer disease. Biochim. Biophys. Acta, 2000; 1502: 1-15
41. Gandy S., Petanceska S.: Regulation of Alzheimer b-amyloid precursor trafficking and metabolism. Biochim. Biophys. Acta, 2000; 1502: 44-52
42. Gebicke-Haerter P.J.: Microglia in neurodegeneration: Molecular aspects. Microsc. Res. Tech., 2001; 54: 47-58
43. Geldmacher D.S.: Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. Expert Rev. Neurother., 2004; 4: 5-16
44. Glabe C.: Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J. Mol. Neurosci., 2001; 17: 137-145
45. Gonzalez-Scarano F., Baltuch G.: Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci.,1999; 22: 219-240
46. Gorczyca W.A.: Cyklazy guanylanowe. Post. Hig. Med. Dos̈w., 1999; 53: 209-222
47. Greig N.H., Sambamurti K., Yu Q.S., Brossi A., Bruinsma G.B., Lahiri D.K.: An overview of phenserine tertrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr. Alzheimer Res., 2005; 2: 281-290
48. Hock C.: Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron, 2003; 38: 547-554
49. Houghton P.J., Howes M.J.: Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease. Neurosignals, 2005; 14: 6-22
50. Huang Y., Liu X.Q., Wyss-Coray T., Brecht W.J., Sanan D.A., Mahley R.W.: Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrilarry tangle-like intracellular inclusions in neurons. Proc. Natl. Acad. Sci. USA, 2001; 98: 8838-8843
51. Ischiropoulos H., Beckman J.S.: Oxidative stress and nitration in neurodegeneration: cause, effects or association? J. Clin. Invest., 2003; 111: 163-169
52. Ishii K., Muelhauser F., Liebl U., Picard M., Kühl S., Penke B., Bayer T., Wiessler M., Hennerici M., Beyreuther K., Hartmann T., Fassbender K.: Subacute NO generation induced by Alzheimer's b-amyloid in the living brain: reversal by inhibition of the inducible NO synthase. FASEB J., 2000; 14:1485-1489
53. Janusz M. Lisowski J.: Kompleks polipeptydowy bogaty w prolinę-włas̈ciwos̈ci immunomodulatorowe i potencjalne mozliwos̈ci zastosowania w przypadku choroby Alzheimera. Zeszyty Naukowe Akademii Rolniczej we Wrocławiu, 2001; 399: 9-17
54. Jones R.W.: Inflammation and Alzheimer's disease. Lancet, 2001; 358; 436-437
55. Kaltschmidt B., Uherek M., Volk B., Baeuerle P.A., Kaltschmidt C.: Transcription factor NF-ęappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer's disease. Proc. Natl. Acad. Sci. USA,1997; 94: 2642-2647
56. Kang S.S., Lee J.Y., Choi Y.K., Song S.S., Kim J.S., Jeon S.J., Han Y.N., Son K.H., Han B.H.: Neuroprotective effects of naturally occurring biflavonoids. Bioorg. Med. Chem. Lett., 2005; 15: 3588-3591
57. Katsuse O., Iseki E., Kosaka K.: Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brain of patients with dementia with Lewy bodies. Neuropathology, 2003; 23: 9-15
58. Klink M., Cedzyński M.: Tlenek azotu jako regulator niektórych funkcji układu odpornos̈ciowego. Post. Biol. Kom., 1999; 26: 775-791
59. Lahiri D.K., Chen D., Ge Y.W., Farlow M., Kotwal G., Kanthasamy A., Ingram D.K., Greig N.H.: Does nitric oxide synthase contribute to the pathogenesis of Alzheimer's disease?: effects of beta-amyloid deposition on NOS in transgenic mouse brain with AD pathology. Ann. N. Y. Acad. Sci., 2003; 1010: 639-642
60. Law A., Gauthier S., Quirion R.: Say NO to Alzheimer's disease: The putative links between nitric oxide and dementia of the Alzheimer's type. Brain Res. Brain Res. Rev., 2001; 35: 73-96
61. Licinio J., Prolo P., McCann S.M., Wong M.L.: Brain iNOS: current understanding and clinical implications. Mol. Med. Today, 1999; 5: 225-232
62. Lynch T., Cherny R.A., Bush A.I.: Oxidative processes in Alzheimer's disease: The role of Ab-metal interactions. Exp. Gerontol., 2000; 35: 445-451
63. Maccioni RB., Munoz J.P., Barbeito L.: The molecular basis of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res., 2001; 32: 367-381
64. Markesbery W.R.: The role of oxidative stress in Alzheimer disease. Arch. Neurol., 1999; 56: 1449-1452
65. Markesbery W.R., Carney J.M.: Oxidative alterations in Alzheimer's disease. Brain Pathol., 1999; 9: 133-146
66. Marui W., Iseki E., Ueda K., Kosaka K.: Occurrence of human a-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer's disease, J. Neurol. Sci., 2000; 174: 81-84
67. Mattson M.P.: Pathways towards and away from Alzheimer's disease. Nature, 2004; 430: 631-639
68. Mazur-Kolecka B., Frąckowiak J., Le Vine H. III, Haske T., Wis̈niewski H.M.: Factors produced by activated macrophages reduce accumulation of Azheimer's b-amyloid protein in vascular smooth muscle cells. Brain Res., 1997; 760: 255-260
69. Meda L., Baron P., Prat E., Scarpini E., Scarlato G., Cassatella M.A., Rossi F. J.: Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid (25-35). J. Neuroimmunol., 1999; 93: 45-52
70. Meda L., Cassatella M.A., Szendrei G.I., Otvos L.Jr., Baron P., Villalba M., Ferrari D., Rossi F.: Activation of the microglial cells by b amyloid protein and interferon g. Nature, 1995; 374: 647-650
71. Meininger C.J., Wu G.: L-glutamine inhibits nitric oxide synthesis in bovine venular endothelial cells. J. Pharmacol. Exp. Ther., 1997; 281: 448-453
72. Miyakawa T., Kimura T., Hirata S., Fujise N., Ono T., Ishizuka K., Nakabayashi J.: Role of blood vessels in producing pathological changes in the brain with Alzheimer's disease. Ann. NY Acad. Sci., 2000; 903: 46-54
73. Moncada S, Palmer R.M., Higgs E.A.: Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev., 1991; 43: 109-142
74. Monsonego A., Weiner H.L.: Immunotherapeutic approaches to Alzheimer's disease. Science, 2003; 302: 834-838
75. Morris S.M.Jr., Billiar T.R.,: New insight into the regulation of inducible nitric oxide synthesis. Am. J. Physiol., 1994; 266: E829-E839
76. Naidu A., Catalano R., Bales K., Wu S., Paul S.M., Cordell B.: Conversion of brain apolipoprotein E to an insoluble form in a mouse model of Alzheimer disease. Neuroreport, 2001; 12: 1265-1270
77. Nakamura Y.: Regulating factors for microglial activation. Biol. Pharm. Bull., 2002; 25; 945-953
78. Octave J.N., Essalmani R., Tasiaux B., Menager J., Czech C., Mercken L.: The role of presenilin-1 in the g-secretase cleavage of the amyloid precursor protein of Alzheimer's disease. J Biol. Chem., 2000; 275: 1525-1528
79. Oliveira A.A. Jr, Hodges H.M.: Alzheimer's disease and neural transplantation as protective cell therapy. Curr. Alzheimer Rev., 2005; 2: 79-95
80. Palmer R.M., Ashton D.S., Moncada S.: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature, 1988; 333: 664-666
81. Pappolla M.A., Bryant-Thomas T.K., Herbert D., Pacheco J., Fabra Garcia M., Manjon M., Girones X., Henry T.L., Matsubara E., Zambon D., Wolozin B., Sano M., Cruz-Sanchez F.F., Thal L.J., Petanceska S.S., Refolo L.M.: Mild hypercholesterolemia in an early risk factor for the development of Alzheimer amyloid pathology. Neurology, 2003: 61:199-205
82. Pappolla M.A., Smith M.A., Bryant-Thomas T., Bazan N., Petanceska S., Perry G., Thal L.J., Sano M., Refolo L.M.: Cholesterol, oxidative stress and Alzheimer's disease: expanding then horizons of pathogenesis. Free Radic. Biol. Med., 2002; 33: 173-181
83. Pennisi E.: Enzymes point way to potential Alzheimer's therapies. Science, 1999; 286: 650-651
84. Pennypacker K.R., Kassed C.A., Eidizadeh S., O'Callaghan J.P.: Brain injury: prolonged induction of transcription factors. Acta Neurobiol. Exp., 2000; 60: 515-530
85. Perry G., Castellani R.J., Smith M.A., Harris P.L., Kubat Z., Ghanbari K., Jones P.K., Cordone G., Tabaton M., Wolozin B., Ghanbari H.: Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol., 2003; 106: 552-556
86. Pheiffer S., Lass A., Schmidt K., Mayer B.: Protein tyrosine nitration in mouse peritoneal macrophages activated in vitro and in vivo: evidence against an essential role of peroxynitrite. FASEB J., 2001; 15: 2355-2364
87. Pickhardt M., von Bergen M., Gazova Z., Hascher A., Biernat J., Mandelkow E.M., Mandelkow E.: Screening for inhibitors of tau polymerization. Curr. Alzheimer Res., 2005; 2: 219-226
88. Potyk D.: Treatments for Alzheimer's disease. South Med. J., 2005; 98: 628-635
89. Prast H., Phillippu A.: Nitric oxide releases acetylocholine in the basal forebrain. Eur. J. Pharmacol., 1992; 216: 139-140
90. Quan N., Herkenham M.: Connecting cytokines and brain: A review of current issues. Histol. Histopathol., 2002; 17: 273-288
91. Ringheim G.E., Szczepanik A.M., Burgher K.L., Petko W., Heronx J.A., Cavalieri F.: Transcriptional inhibition of the beta-amyloid precursor protein by interferon gamma. Biochem. Biophys. Res. Commun., 1996; 224: 246-251
92. Ringman J.M., Frautschy S.A., Cole G.M., Masterman D.L., Cummings J.L.: A potential role of the curry spice curcumin in Alzheimer's disease. Curr. Alzheimer Res., 2005; 2: 131-136
93. Rodrigo J., Alonso D., Bentura M.L., Castro-Blanco S., Encinas J.M., Fernandez A.P., Fernandez-Vizarra P., Richard A., Santacana M., Serrano J., Martinez A.: Physiology and patophysiology of nitric oxide in the nervous system, with special mention of the islands of Calleja and the circunventricular organs. Histol. Histopathol., 2002; 17: 973-1003
94. Rogers J., Lue L.F.: Microglial chemotaxis, activation and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem. Int., 2001; 39: 333-340
95. Rogers J., Strohmeyer R., Kovelowski C.J., Li R.: Microglia and inflammatory mechanisms of clearance of amyloid b peptide. Glia, 2002; 40: 260-269
96. Roitt I., Brostoff J., Male D.: Reakcje immunologiczne typu komórkowego. W: Immunologia. (red. Zeromski J.), Wyd. Medyczne Słotwiński Verlag i Wyd. Lekarskie PZWL 2000, 121-125
97. Saez Valero J., Mok S.S., Small D.H.: An unusually glycosylated form of acetylcholinesterase is a CSF biomarker of Alzheimer disease. Acta Neurol. Scand. Suppl., 2000; 177: 49-52
98. Sayre L.M., Smith M.A., Perry G.: Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem., 2001; 8: 721-738
99. Selkoe D.J.: Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2001; 98: 11039-11041
100. Serpell L.C.: Alzheimer's amyloid fibrils: structure and assembly. Biochim. Biophys. Acta, 2000; 1502: 16-30
101. Shepherd A.J., Downing J.E., Miyan J.A.: Without nerves, immunology remains incomplete-in vivo veritas. Immunology, 2005; 116: 145-163
102. Siemers E., Skinner M., Dean R.A., Gonzales C., Satterwhite J., Farlow M., Ness D., May P.C.: Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin. Neuropharmacol., 2005; 28: 126-132
103. Simonian N.A., Coyle J.T.: Oxidative stress in neurodegenerative diseases. Ann. Rev. Pharmacol. Toxicol., 1996; 36: 83-106
104. Skrzydlewska E., Farbiszewski R.: Interakcje wolnych rodników z białkami. Post. Hig. Med. Dos̈w., 1995; 49: 747-766
105. Small G.W., Kaufer D., Mendiondo M.S., Quarg P., Spiegel R.: Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int. J. Clin. Pract., 2005; 59: 473-477
106. Smidth T.L., Steiner E., Klinger P., Sztankay A., Grubeck-Loebstein B.: The production of an amyloidogenic metabolite of the Alzheimer amyloid precursor protein (APP) in tyroid cells is stimulated by interleukin 1 but inhibited by interferon gamma. J. Clin. Endocrynol. Metab., 1996; 81: 1666-1669
107. Srebro Z., Wiliński B., Sura P.: Stres oksydacyjny w chorobie Alzheimera. Folia Medica Cracoviensia, 2000; 41: 165-170
108. Strle K., Zhou J.H., Shen W.H., Broussard S.R., Johnson R.W., Freund G.G., Dantzer R., Kelley K.W.: Interleukin-10 in the brain. Crit. Rev. Immunol., 2001; 21: 427-449
109. Suh Y.H., Checler F.: Amyloid precursor protein, presenilins, and a-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev., 2002; 54: 469-525
110. Sun A.Y., Chen Y.M.: Oxidative stress and neurodegenerative diseorders. J. Biomed. Sci., 1998; 5: 401-414
111. Tamura Y., Hamajima K., Matsui K., Yanoma S., Narita M., Tajima N., Xin K.Q., Klinman D., Okuda K.: The F(ab')2 fragment of A beta-specific monoclonal antibody reduces A beta deposits in the brain. Neurobiol. Dis., 2005; 20: 541-549
112. Vetulani J.: Perspektywy terapii choroby Alzheimera. Psychogeriatria Polska, 2004; 1: 253-278
113. Walter J., Kaether C., Steiner H., Haass C.: The cell biology of Alzheimer's disease. Uncovering the secrets of secretases. Curr. Opin. Neurobiol., 2001; 11: 585-590
114. Weksler M.E., Gouras G., Relkin N.R., Szabo P.: The immune system, amyloid b peptide and Alzheimer's disease. Immunol. Rev., 2005; 205: 244-256
115. Yanagisawa K.: Cholesterol and pathological processes in Alzheimer's disease. J. Neurosci. Res., 2002; 70: 361-366
116. Zdzisińska B., Kandefer-Szerszeń M.: Rola tlenku azotu w prawidłowych i patologicznych reakcjach odpornos̈ciowych. Post. Hig. Med. Dos̈w., 1998; 52: 621-636
117. Zujovic V., Benavides J., Vige X., Carter C., Taupin V.: Fractalkine modulates TNF-A secretion and neurotoxicity induced by microglial activation. Glia, 2000; 29: 305-315